Human Psychopharmacology
Clinical and Experimental

VOLUME 5

EDITOR-IN-CHIEF **Dr J Guy Edwards**
Department of Psychiatry, Royal South Hants Hospital, Southampton SO9 4PE, UK.
Tel: 0703 634288 (Office)

EDITORS

Dr Philip Cowen
Medical Research Council,
Littlemore Hospital, Oxford OX4 4XN, UK

Dr Ian Hindmarch
Human Psychopharmacology Research Unit, Robens Institute,
University of Surrey, Guildford GU2 5XH, UK

Dr Michael R Trimble
The National Hospitals for Nervous Diseases,
Queen Square, London WC1N 3BG, UK

Dr Guy M Goodwin
MRC Brain Metabolism Unit, Royal Edinburgh Hospital,
Morningside Park, Edinburgh EH10 5HF, UK

Professor Brian E Leonard
Pharmacology Department, University College,
Galway, Republic of Ireland

AIMS AND SCOPE

Human Psychopharmacology aims to communicate the results of clinical and experimental studies relevant to the understanding of new and established psychoptropic drugs. To this end the journal publishes articles on the following topics:

- ★ Experimental human psychopharmacology
- ★ Efficacy studies in humans, especially large-scale and placebo controlled trials
- ★ Volunteer studies
- ★ Relevant animal studies
- ★ Effects of psychotropic drugs on physiological systems, including unwanted effects
- ★ Psychotropic drug use and dependence
- ★ Broader ethical psychological and sociological aspects of drug use, misuse and abuse

The content of *Human Psychopharmacology* comprises *Original articles, Short communications* (not exceeding 1500 words). *Reviews* and *Comments* by leading authorities with discussion by other experts, papers on *Practical therapeutics,* report of *International meetings, Book reviews, Correspondence* and *Diary.*

EDITORIAL POLICY

The Editors' policy is to encourage and publish contributions on all aspects of human psychopharmacology. *Human Psychopharmacology* is a multidisciplinary journal and articles dealing with the broader aspects of pharmacotherapy in a social and clinical setting are welcomed. All original articles and short communications are strictly refereed and only studies meeting acceptable ethical standards governing experimentation on animals and man will be considered. Proceedings of meetings and symposia that meet strict editorial criteria may be published as supplements to the journal.
Human Psychopharmacology aims to publish contributions within three to six months of final acceptance.

EDITORIAL ADVISORY BOARD

J. Angst
Zurich, Switzerland
R. J. Baldessarini
Belmont, USA
R. H. Belmaker
Beer Sheva, Israel
G. D. Burrows
Victoria, Australia
A. Carlsson
Goteborg, Sweden
S. J. Cooper
Birmingham, UK
J. F. W. Deakin
Manchester, UK
S. E. File
London, UK
G. M. Goodwin
Edinburgh, UK
S. R. Hirsch
London, UK
L. E. Hollister
Houston, Texas, USA
K. Inanaga
Kurume, Japan
J. J. Lopez-Ibor, Jr
Madrid, Spain
J. Maj
Krakow, Poland
D. J. Nutt
Bristol, UK
T. Okuma
Tokyo, Japan
A. Puech
Paris, France
R. Rimón
Helsinki, Finland
M. Roth
Cambridge, UK
T. Roth
Detroit, USA
B. Saletu
Vienna, Austria
M. Schou
Risskov, Denmark
G. Sedvall
Stockholm, Sweden
S. H. Snyder
Maryland, USA
F. Sulser
Tennessee, USA
P. Turner
London, UK
P. J. Tyrer
London, UK
H. M. van Praag
New York, USA
M. E. Vartanian
Zagorodnoje, Russia
D. Waller
Southampton, UK
D. Wheatley
Surrey, UK

COPYING OF ARTICLES

The code and the copyright notice appearing at the bottom of the first page of an article in this journal indicates the copyright owner's consent that copies of the article may be made for personal or internal use, or for the personal or internal use of specific clients, on the condition that the copier pay for copying beyond that permitted by Sections 107 or 108 of the U.S. Copyright Law. The per-copy fee for each article appears after the dollar sign, and is to be paid through the Copyright Clearance Center Inc. The consent does not extend to other kinds of copying such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale. Such permission requests, or other inquiries, should be addressed to the publisher.

CONTENTS

Volume 5, Issue Nos 1–4

HUMAN PSYCHOPHARMACOLOGY

Issue No. 1 March 1990

Editorial
(Re-)minding Our Business: **H. M. van Praag** 1

Review
Does Electroconvulsive Shock Therapy Work Through Opioid Mechanisms?: **H. C. Jackson and D. J. Nutt** 3

Original Articles
The Lack of CNS Effects of Nizatidine, With and Without Alcohol, on Psychomotor Ability and Cognitive Function: **I. Hindmarch and S. Gilburt** 25

Some Factors Related to the Use of Psychoactive Drugs, in an Institution for Adults with Mental Handicap: **P. Harlow, S. Morton and E. Wright** 33

The Comparative Cognitive Side-effects of Lithium, Carbamazepine and Combined Lithium–Carbamazepine in Patients Treated for Affective Disorders: **D. G. Andrews, I. Schweitzer and N. Marshall** 41

Creating Equivalent Word Lists for the Buschke Selective Reminding Test: **R. F. Coen, A. Kinsella, R. Lambe, M. Kenny and A. Darragh** 47

The Measurement of Body Sway: **R. F Coen, G. K. Neill, R. Lambe and A. Darragh** 53

The Use of Flumazenil in Prevention of Diazepam Dependence in the Rat: **H. A. Baldwin, P. K. Hitchcott and S. E. File** 57

Letter
Fluoxetine in the Treatment of Obsessive Compulsive Disorders: **A. Eisen** 63

Book Reviews
Synaptic Function, reviewed by **B. E. Leonard** 64

The Neuro-Immune-Endocrine Connection, reviewed by **C. Thompson** 65

Geriatric Clinical Pharmacology, reviewed by **J. P. Wattis** 66

Neuronal Serotonin, reviewed by **E. F. Marshall** 67

Therapeutic Risk-Perception, Measurement, Management, reviewed by **C. M. H. Nunn** 67

Anxiety and its Disorders: The Treatment of Anxiety and Panic, reviewed by **S. Brandon** 68

Abstracts
British Sleep Society Inaugural Meeting 4–5 September 1989, Edinburgh: Guest Editors, **C. M. Shapiro and N. J. Douglas** 69

Issue No. 2 June 1990

Editorial
Social Phobia and Pharmacotherapy: **M. Versiani** 103

Review
Schizophrenia: Basic, Release, Reactive and Defect Processes: **D. Healy** 105

Original Articles
Computer-analysed EEG and Psychometric Assessment of Two New Non-benzodiazepine Tranquillizers in Healthy Volunteers: **A. Patat, M. J. Klein, M. Hucher and J. Granier** 123

A Double-blind Comparative Trial of Remoxipride and Haloperidol in the Treatment of Schizophrenia: **R. Deo, S. Soni, S. C. Rastogi, S. Levine, I. Plant, J. Guy Edwards, M. J. Mitchell and A. Chanas** 133

The Effects of Diazepam on Cognitive Processing: **S. Golombok, A. Mathews, C. Macleod and M. Lader** 143

Effects of an Alpha-2 Adrenoceptor Antagonist, Org 3770, Upon the Autonomic Function of the Pupil: **E. Palazidou, J. M. A. Sitsen and S. A. Checkley** 149

Effects of Tranylcypromine on Serotonin Content and Monoamine Oxidase Activity of the Human Blood Platelet: **G. F. Oxenkrug, R. Balon, R. B. McCauley and I. M. McIntyre** 155

Clinical Evaluation of Alprazolam in Patients with Panic Disorder: a Double-Blind Comparison with Imipramine: **J. Lepola, H. Heikkinen, R. Rimón and P. Riekkinen** 159

Relationship Between Tardive Dyskinesia and Psychopathology in a Group of Schizophrenic Patients Attending a Rehabilitation Centre: **A. Perenyi, G. Zador and S. Horvath** 165

Age and Anxiety: Increased Anxiety, Decreased Anxiolytic, but Enhanced Sedative, Response to Chlordiazepoxide in Old Rats: **S. E. File** 169

Letters
Tricyclic Antidepressant Induced Mania: Rapid Switch or Slow Oxidation: **M. Toutoungli** 175

Ethics of Placebo-controlled Trials in Depression: **S. Brandon** 176

Ethics of Placebo-controlled Trials in Depression Replies: **T. J. Fahy** 177

Book Review
Neurotoxins in Neurochemistry, reviewed by **J. M. O'Donnell** 179

Announcement 180

Issue No. 3 September 1990

Editorial
New Concepts in Anxiety: **M. Briley** 181

Review
Kinins in the Brain: **C. D. Figueroa, K. Worthy and K. D. Bhoola** 183

Original Articles
The Long-term Use of Psychotropic Drugs: a Follow-up Study in Italian General Practice: **R. Fiorio, C. Bellantuono, M. Leoncini, G. Montemezzi, R. Micciolo and P. Williams** 195

The Effects of Single and Repeated Doses of Oral Scopolamine, Cinnarizine, and Placebo upon Psychological Performance and Physiological Functioning: **A. C. Parrott, J. F. Golding and R. J. Pethybridge** 207

Comparison of Zopiclone and Flurazepam Treatments in Insomnia: **A. N. Singh and J. Bourgouin** 217

Combined Serotonin-5-HT_2 and Dopamine-D_2 Antagonism in Schizophrenia: Clinical, Extrapyramidal and Neuroendocrine Response in a Preliminary Study with Risperidone (R 64 766): **G. Bersani, G. M. Bressa, G. Meco, S. Marini and F. Pozzi** 225

Sulpiride in Negative Schizophrenia: A Placebo-controlled Double-blind Assessment: **D. Soni, A. Mallik and A. A. Schiff** 233

Significantly Increased Urinary Free Cortisol Excretion in Melancholic Depressed Females During L-Tryptophan Loading: **M. Maes, B. Minner, E. Suy and P. D'Hondt** 239

The Effect of Acute Alcohol Intoxication on Psychometric Testing and 5-HT-induced Platelet Aggregation in Normal Subjects: Modulatory Role of Evening Primrose Oil: **R. Corbet, J. B. A. Meagher and B. E. Leonard** 245

Comment

Neuroendocrine Function and the Biology of the Eating Disorders: **G. M. Goodwin** 249

Letter

Ethics of Placebo-controlled Trials in Depression: **S. Hirsch** 255

Book Reviews

Handbook of Parkinson's Disease, reviewed by **R. H. S. Mindham** 256

The Psychopharmacology of Anxiety, reviewed by **D. Wheatley** 257

Elements of Molecular Neurobiology, reviewed by **B. E. Leonard** 257

Neurotransmitters, Drugs and Disease, reviewed by **B. E. Leonard** 258

Therapeutic Risk: Perception, Measurement, Management, reviewed by **B. E. Leonard** 259

Life in Research, reviewed by **B. Steinberg** 259

Announcement 260

Supplement

Combined Lithium/Neuroleptic Therapy for Manic-Depressive Illness
Guest Editors—D. A. W. Johnson, M. R. Lowe and D. H. Batchelor

Preface: **M. R. Lowe and D. H. Batchelor** 262

Adverse Lithium-Neuroleptic Interactions—Are There Permanent Effects: **M. Schou** 263

Lithium and Neuroleptics in the Management of Manic Depressive Psychosis: **M. R. Lowe and D. H. Batchelor** 267

Reported Neurotoxicity with the Lithium/Haloperidol Combination and Other Neuroleptics—A Literature Review: **D. H. Batchelor and M. R. Lowe** 275

Lithium Neurotoxicty—The Reliability of Serum Lithium Measurements: **A. Amdisen** 281

Possible Mechanisms for the Presumed Interaction Between Lithium and Neuroleptics: **L. Von Knorring** 287

Some Pharmacological Aspects Relating to the Issue of Possible Neurotoxic Interactions During Combined Lithium-Neuroleptic Therapy: **J. L. Waddington** 293

Issue No. 4 December 1990

Editorial
To Act or Not to Act? That is the Question: **P. Turner** 299

Review
Long-Term Benzodiazepine Treatment: Is it Ever Justified?: **Y. Chen and M. Lader** 301

Original Articles
Tyramine-induced Cardiac Arrhythmias: **J. W. G. Tiller, K. P. Maguire, B. M. Davies, J. T. Dowling, L. H. Tung and M. J. Rand** 313

Study of the Potential Pharmacodynamic Antagonism of RU 41 656 on Scopolamine and Triazolam Impairment in Healthy Subjects: **A. Patat, M. J. Klein, A. Surjus, M. Hucher and J. Granier** ... 323

Effects of Repeated Caffeine Administration on Cognition and Mood: **W. H. Loke** 339

High-Dose Anabolic Steroids in Strength Athletes: Effects upon Hostility and Aggression: **P. Y. L. Choi, A. C. Parrott and D. Cowan** 349

Effect of Hydroxyzine on Attention and Memory: **A. de Brabander and W. Deberdt** 357

Effect of Ceruletide on Microvibration in Schizophrenics: **T. Nishikawa, H. Kuwahara, A. Tsuda, M. Tanaka, I. Koga and Y. Uchida** 363

Comparison of Mianserin and Dothiepin Treatment on the Serotonergic System in Depressed Patients: **J. Butler and B. E. Leonard** 369

Letters to Editors
Ethics of Placebo-controlled Trials in Depression:
T. R. Norman, F. K. Judd and G. D. Burrows 373
J. Guy Edwards 374
R. C. Winning 375

Book Review
Contemporary Approaches to Psychological Assessment, reviewed by **A. Dobbs** 376

Author Index 377

Keyword Index 378